Newborn screening (NBS) is justified if early intervention is effective in a disorder generally not detected early in life on a clinical basis, and if sensitive and specific biochemical markers exist. Experience with NBS for homocystinurias and methylation disorders is limited. However, there is robust evidence for the success of early treatment with diet, betaine and/or pyridoxine for CBS deficiency and good evidence for the success of early betaine treatment in severe MTHFR deficiency. These conditions can be screened in dried blood spots by determining methionine (Met), methionine-to-phenylanine (Met/Phe) ratio, and total homocysteine (tHcy) as a second tier marker. Therefore, we recommend NBS for cystathionine beta-synthase and severe MTHFR deficiency. Weaker evidence is available for the disorders of intracellular cobalamin metabolism. Early treatment is clearly of advantage for patients with the late-onset cblC defect. In the early-onset type, survival and non-neurological symptoms improve but the effect on neurocognitive development is uncertain. The cblC defect can be screened by measuring propionylcarnitine, propionylcarnitine-to-acetylcarnitine ratio combined with the second tier markers methylmalonic acid and tHcy. For the cblE and cblG defects, evidence for the benefit of early treatment is weaker; and data on performance of Met, Met/Phe and tHcy even more limited. Individuals homozygous or compound heterozygous for MAT1A mutations may benefit from detection by NBS using Met, which on the other hand also detects asymptomatic heterozygotes. Clinical and laboratory data is insufficient to develop any recommendation on NBS for the cblD, cblF, cblJ defects, glycineN-methyltransferase-, S-adenosylhomocysteinehydrolase- and adenosine kinase deficiency.

Centro de Diagnóstico de Enfermedades Moleculares Facultad de Ciencias Universidad Autónoma de Madrid IDIPAZ CIBER de Enfermedades Raras Madrid Spain

Department Laboratory Medicine and Pathology Mayo Clinic Rochester MN USA

Department of Neuroscience Newborn Screening Unit A Meyer University Children's Hospital Florence Italy

Division Inborn Errors of Metabolism Hospital Clinic CIBERER Barcelona Spain

Division of Metabolism and Children's Research Center University Children's Hospital Zürich Zürich Switzerland Radiz Rare Disease Initiative Zürich University Zürich Zürich Switzerland

Division of Metabolism and Children's Research Center University Children's Hospital Zürich Zürich Switzerland Radiz Rare Disease Initiative Zürich University Zürich Zürich Switzerland Department of Pediatrics Landeskrankenhaus Bregenz Carl Pedenz Str 2 6900 Bregenz Austria

Institute of Inherited Metabolic Disorders Charles University Prague 1st Faculty of Medicine and General University Hospital Prague Czech Republic

Laboratory Clinical Biochemistry and Metabolism Center for Pediatrics and Adolescent Medicine University Hospital Freiburg Freiburg Germany

000      

00000naa a2200000 a 4500

001      

bmc16028475

003      

CZ-PrNML

005      

20161025103037.0

007      

ta

008      

161005s2015 ne f 000 0|eng||

009      

AR

024    7_

$a 10.1007/s10545-015-9830-z $2 doi

024    7_

$a 10.1007/s10545-015-9830-z $2 doi

035    __

$a (PubMed)25762406

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a ne

100    1_

$a Huemer, Martina $u Division of Metabolism and Children's Research Center, University Children's Hospital Zürich, Zürich, Switzerland. martina.huemer@lkhb.at. Radiz-Rare Disease Initiative Zürich, University Zürich, Zürich, Switzerland. martina.huemer@lkhb.at. Department of Pediatrics, Landeskrankenhaus Bregenz, Carl-Pedenz-Str. 2, 6900, Bregenz, Austria. martina.huemer@lkhb.at.

245    10

$a Newborn screening for homocystinurias and methylation disorders: systematic review and proposed guidelines / $c M. Huemer, V. Kožich, P. Rinaldo, MR. Baumgartner, B. Merinero, E. Pasquini, A. Ribes, HJ. Blom,

520    9_

$a Newborn screening (NBS) is justified if early intervention is effective in a disorder generally not detected early in life on a clinical basis, and if sensitive and specific biochemical markers exist. Experience with NBS for homocystinurias and methylation disorders is limited. However, there is robust evidence for the success of early treatment with diet, betaine and/or pyridoxine for CBS deficiency and good evidence for the success of early betaine treatment in severe MTHFR deficiency. These conditions can be screened in dried blood spots by determining methionine (Met), methionine-to-phenylanine (Met/Phe) ratio, and total homocysteine (tHcy) as a second tier marker. Therefore, we recommend NBS for cystathionine beta-synthase and severe MTHFR deficiency. Weaker evidence is available for the disorders of intracellular cobalamin metabolism. Early treatment is clearly of advantage for patients with the late-onset cblC defect. In the early-onset type, survival and non-neurological symptoms improve but the effect on neurocognitive development is uncertain. The cblC defect can be screened by measuring propionylcarnitine, propionylcarnitine-to-acetylcarnitine ratio combined with the second tier markers methylmalonic acid and tHcy. For the cblE and cblG defects, evidence for the benefit of early treatment is weaker; and data on performance of Met, Met/Phe and tHcy even more limited. Individuals homozygous or compound heterozygous for MAT1A mutations may benefit from detection by NBS using Met, which on the other hand also detects asymptomatic heterozygotes. Clinical and laboratory data is insufficient to develop any recommendation on NBS for the cblD, cblF, cblJ defects, glycineN-methyltransferase-, S-adenosylhomocysteinehydrolase- and adenosine kinase deficiency.

650    _2

$a acylkarnitin $x krev $7 D000108

650    _2

$a betain $x terapeutické užití $7 D001622

650    _2

$a karnitin $x analogy a deriváty $x krev $7 D002331

650    _2

$a homocystinurie $x diagnóza $7 D006712

650    _2

$a lidé $7 D006801

650    _2

$a novorozenec $7 D007231

650    _2

$a methionin $x krev $7 D008715

650    _2

$a metylace $7 D008745

650    _2

$a methylentetrahydrofolátreduktasa (NADPH2) $x nedostatek $x účinky léků $7 D042965

650    _2

$a kyselina methylmalonová $x krev $7 D008764

650    12

$a novorozenecký screening $7 D015997

650    _2

$a směrnice pro lékařskou praxi jako téma $7 D017410

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

655    _2

$a přehledy $7 D016454

700    1_

$a Kožich, Viktor $u Institute of Inherited Metabolic Disorders, Charles University in Prague-1st Faculty of Medicine and General University Hospital, Prague, Czech Republic.

700    1_

$a Rinaldo, Piero $u Department Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.

700    1_

$a Baumgartner, Matthias R $u Division of Metabolism and Children's Research Center, University Children's Hospital Zürich, Zürich, Switzerland. Radiz-Rare Disease Initiative Zürich, University Zürich, Zürich, Switzerland.

700    1_

$a Merinero, Begoña $u Centro de Diagnóstico de Enfermedades Moleculares, Facultad de Ciencias, Universidad Autónoma de Madrid, IDIPAZ, CIBER de Enfermedades Raras, Madrid, Spain.

700    1_

$a Pasquini, Elisabetta $u Department of Neuroscience, Newborn Screening Unit, A. Meyer University Children's Hospital, Florence, Italy.

700    1_

$a Ribes, Antonia $u Division Inborn Errors of Metabolism, Hospital Clinic, CIBERER, Barcelona, Spain.

700    1_

$a Blom, Henk J $u Laboratory Clinical Biochemistry and Metabolism, Center for Pediatrics and Adolescent Medicine University Hospital, Freiburg, Freiburg, Germany.

773    0_

$w MED00002747 $t Journal of inherited metabolic disease $x 1573-2665 $g Roč. 38, č. 6 (2015), s. 1007-19

856    41

$u https://pubmed.ncbi.nlm.nih.gov/25762406 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y a $z 0

990    __

$a 20161005 $b ABA008

991    __

$a 20161025103451 $b ABA008

999    __

$a ok $b bmc $g 1166789 $s 953105

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2015 $b 38 $c 6 $d 1007-19 $e 20150312 $i 1573-2665 $m Journal of inherited metabolic disease $n J Inherit Metab Dis $x MED00002747

LZP    __

$a Pubmed-20161005